TRACE-RMD: TReAtment With Concurrent Exercise in Patients With Resistant Major Depression

Sponsor
University of the Basque Country (UPV/EHU) (Other)
Overall Status
Recruiting
CT.gov ID
NCT05136027
Collaborator
Red Salud Mental Araba (Other)
20
1
1
6
3.3

Study Details

Study Description

Brief Summary

The aim is to apply an exercise program to study symptomatic and physical changes, as well as to evaluate the improvement in functionality in a resistant depression unit. Sample: 20 patients with the resistant major depressive disorder who will undergo an exercise program. Before and after 12 weeks of intervention, the participants will be assessed with clinical, physical, physiological, biochemical, and functional variables. During 3 months the exercise program will be implemented 2 days per week. It is expected to find an improvement in mood and functionality, as well as changes in physical areas such as blood pressure or body mass index, which are considered predictive factors of cardiovascular disease.

Condition or Disease Intervention/Treatment Phase
  • Other: Concurrent training
N/A

Detailed Description

The presence of major depressive disorder (MDD) in today's society is worryingly high. Specifically, the prevalence-year prevalence of MDD in Spain is 3.9% and lifetime prevalence is 10.5%. The lifetime prevalence for men is 6.29% and 14.47% for women in Spain according to the ESEMED-Spain study. Although there is no explicit international consensus, the medical literature and research define treatment-resistant depression (TRD) as any MDD that does not respond to two trials of treatment antidepressant treatment at adequate doses and for an adequate duration of time.

MDD is the leading cause of years lived with disability worldwide, accounting for 11.9%. It has been estimated that during the year 2020 it could be second only to ischemic heart disease in disability-adjusted life years lost. Given this bleak scenario, different non-pharmacological strategies have been considered as possible complementary treatments to pharmacological treatment to help improve the prognosis of MDD and remission rates, such as exercise and electroconvulsive therapy.

Sedentary lifestyles are a very common feature in the severely mentally disordered population. One of the causes for this to occur is that people with MDD have very little confidence in their ability to exercise and lack the necessary social support. This inactivity together with other modifiable risk factors such as tobacco use, high blood pressure, and overweight/obesity, in addition to the side effects of pharmacological treatments contributes to the appearance of different diseases, as well as decreased life expectancy and quality of life. TDM can act as a cause or as a repercussion of physical inactivity.

It has been recognized for several years that the performance of regular exercise is cardioprotective, decreasing the incidence of cardiovascular diseases such as arterial hypertension, coronary artery disease, type 2 diabetes, and atherosclerosis. In addition to being cardioprotective, exercise has shown a positive association with psychological well-being and therapeutic benefits in older people with depressive disorder, depressive symptoms in patients with Alzheimer's disease and MDD.

Although there is still some controversy about the intensity and frequency of exercise, and the duration of the exercise program, the recommendations were the adoption of a moderate-intensity exercise program of at least 30 minutes on most days of the week, for 10-12 weeks. In the latest World Health Organization guidelines on physical activity (PA) and sedentary habits, for the improvement of quality of life in adults with TMD the general recommendations do not differ from the general population, i.e., people should accumulate throughout the week a minimum of 150-300 minutes of moderate aerobic PA or a minimum of 75-150 minutes of vigorous PA, or an equivalent combination of both in order to obtain notable health benefits. Also, in order to achieve additional health benefits, the participants should perform two days a week of moderate or higher intensity muscle-strengthening activities.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Physical exercise groupPhysical exercise group
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effects of Treatment With Concurrent Exercise in Patients With Resistant Major Depression
Anticipated Study Start Date :
Jan 30, 2022
Anticipated Primary Completion Date :
Jun 30, 2022
Anticipated Study Completion Date :
Jul 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention group

Intervention group: In the physical exercise session will carry out a concurrent training in four parts, low- intensity interval training in a bicycle, resistance circuit training, ow- intensity interval training in a bicycle, and CORE exercises.

Other: Concurrent training
Low intensity interval training and resistance exercise

Outcome Measures

Primary Outcome Measures

  1. Montgomery-Asberg Depressión Rating Scale (MADRS) [12 weeks]

    Ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Usual cutoff points are: 0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression

  2. Cardiorespiratory fitness [12 weeks]

    Cardiorespiratory fitness evaluation measured by cardiopulmonary exercise test. Maximu oxygen uptake measured in mL/kg/min or L/min is the gold standard variable.

Secondary Outcome Measures

  1. Clinical Global Impression Scale (CGI) [12 weeks]

    The Clinical Global Impression (CGI) rating scales are measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders. Its 3 items assess, 1) Severity of Illness (CGI-S), 2) Global Improvement (CGI-I), and 3) Efficacy Index (CGI-E, which is a measure of treatment effect and side effects specific to drugs that were administered).

  2. Sheehan Disability Scale (SDS) [12 weeks]

    five-item, self-rated questionnaire designed to measure the extent to which a patient's disability due to an illness or health problem interferes with work/school, social life/leisure activities, and family life/home responsibilities. Total score 0-30 (0 unimpaired, 30 highly impaired) Work/school (0-10) Social life (0-10) Family life/home responsibilities (0-10 Scores of ≥5 on any of the 3 scales; high scores are associated with significant functional impairment.

  3. Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9) [12 weeks]

    To measure patients' satisfaction with medication

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 78 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Depression major disorder.

  • 2 or more antdepressives resistant a treatment.

  • Consent informed signed

Exclusion Criteria:
  • Schizophrenia or other disorders.

  • Suicide risk.

  • Unstable medic illness or unsuitable controlled.

  • Disorder for use of active substances.

  • Comorbidity with other psychiatric pathologies.

  • Montreal Cognitive Assessment <26/30, cognitive deterioration.

  • Incapacity for realizing physical exercise because of osteoarticular, cardiovascular, or metabolic difficulty.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Basque Country University Vitoria Gasteiz Spain

Sponsors and Collaborators

  • University of the Basque Country (UPV/EHU)
  • Red Salud Mental Araba

Investigators

  • Principal Investigator: NAGORE IRIARTE-YOLLER, MD, PSYCHIATRIC HOSPITAL OF ÁLAVA

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
SARA MALDONADO-MARTIN, Head of laboratory, Principal Investigator, University of the Basque Country (UPV/EHU)
ClinicalTrials.gov Identifier:
NCT05136027
Other Study ID Numbers:
  • TRACE-RMD study
First Posted:
Nov 26, 2021
Last Update Posted:
Nov 26, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by SARA MALDONADO-MARTIN, Head of laboratory, Principal Investigator, University of the Basque Country (UPV/EHU)
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 26, 2021